Travere Therapeutics, Inc. · NASDAQ:TVTX
Travere Therapeutics — Technical Presentation (June 2025)
11 slides from Travere Therapeutics's technical presentation, June 2025
Slide 1: Effects of Sparsentan After Maximized ARB Treatment in Patients With IgAN in the PROTECT Trial
Effects of Sparsentan After Maximized Angiotensin Receptor Blocker (ARB) Treatment in Patients With IgA Nephropathy (IgAN) in the PROTECT Trial J FLOEGE,1 DV RIZK,2 P PRECIADO,3* BH ROVIN,4 S MOODY,3 R GELETKA,3 A MERCER,5 B HENDRY,3 R KOMERS,3 V TESAR6 1University of Aachen, Aachen, Germany; 2Unive
Slide 2: Introduction
INTRODUCTION • SPAR is a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA)1 indicated in the US to slow kidney function decline in adults with primary IgAN at risk for disease progression2 and in the EU to treat adults with primary IgAN3 • In the phase 3, randomized, DB
Slide 3: Methods
METHODS PROTECT DB period: • Multicenter, randomized clinical trial (NCT03762850) • Adults with biopsy-proven IgAN and persistent proteinuria despite RASi treatment • Received SPAR (400 mg/d) vs maximum labeled dose IRB (300 mg/d) for 110 weeks, then resumed RASi for 4 weeks (study drug washout) PRO
Slide 4: Patient Demographics and Baseline Characteristics at the Start of the OLE Period
RESULTS Patient Demographics and Baseline Characteristics at the Start of the OLE Period* IRBÆSPAR OLE (n=128) Age at informed consent, mean (SD), y 45.5 (11.99) Male sex, n (%) 91 (71) Race, n (%)† Asian 27 (21) Black or African American 1 (1) Native Hawaiian or Other Pacific Islander 1 (1) White 9
Slide 5: UPCR at Each Study Visit for Patients Randomized to IRB
RESULTS UPCR at Each Study Visit for Patients Randomized to IRB • SPAR showed a rapid reduction in UPCR that was sustained for up to 48 weeks in the OLE period DB period IRB washout OLE period (patients randomized to IRB) (4 weeks) (patients from IRB group who initiated SPAR) 1.6 1.6 IRB SPAR 1.4 1.
Slide 6: eGFR values at Each Visit Period
RESULTS eGFR values at Each Visit in the OLE Period • eGFR values remained consistent for up to 48 weeks in the OLE period 70 60 eGFR, mean (SE), mL/min/1.73 m2 50 40 30 0 2 12 24 36 48 Week n=127 122 124 120 121 118 eGFR, estimated glomerular filtration rate; OLE, open-label extension. MA-SP-25-008
Slide 7: BP at Each Visit Period
RESULTS BP at Each Visit in the OLE Period • BP remained well controlled throughout the OLE • At 48 weeks, mean changes (SD) from OLE baseline in SBP and DBP were −1.0 (11.03) and −2.2 (8.82) mm Hg, respectively SBP DBP BP, mean (SD), mm Hg 160 140 120 100 80 60 40 20 0 0 2 12 24 36 48 Week n=127 12
Slide 8: Safety Period
RESULTS Safety in the OLE Period • Rates of AEs in the OLE were low, with no new safety signals identified IRBÆSPAR OLE (n=128) Patients with any TEAE, n (%) 103 (80) Any TEAEs in ≥5% of patients, n (%) COVID-19 23 (18) Hyperkalemia 15 (12) Peripheral edema 13 (10) Upper respiratory tract infection
Slide 9: Conclusions
CONCLUSIONS Patients previously treated with maximum labeled dose IRB for 2 years experienced rapid and sustained proteinuria reductions with SPAR SPAR treatment was generally well tolerated, with stable blood pressure and no new safety signals IRB, irbesartan; SPAR, sparsentan. MA-SP-25-0083 06/202
Slide 10: References
REFERENCES 1. Kohan DE, et al. Clin Sci (Lond). 2024;138(11):645-662. 2. Filspari (sparsentan). Prescribing information. Travere Therapeutics, Inc.; 2024. 3. Filspari (sparsentan). Summary of product characteristics. CSL Vifor; 2024. 4. Rovin BH, et al. Lancet. 2023;402(10417):2077-2090. MA-SP-25-00
Slide 11: Disclosures
DISCLOSURES • JF reports consulting fees, honoraria, and speakers bureaus from AstraZeneca, Bayer, Boehringer Ingelheim, Calliditas, CSL Vifor, HI-Bio Novo Nordisk, Novartis, Omeros, Otsuka, Roche, Stada, Travere Therapeutics, Inc., Vera Therapeutics, and Visterra. • DVR reports grants/research supp
Travere Therapeutics — Technical Presentation (June 2025) on 6ix